The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Diethyl 4-(3-methoxy-4-(3-(piperidin-1-yl)propoxy)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate ID: ALA4547812
PubChem CID: 155553729
Max Phase: Preclinical
Molecular Formula: C28H40N2O6
Molecular Weight: 500.64
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccc(OCCCN2CCCCC2)c(OC)c1
Standard InChI: InChI=1S/C28H40N2O6/c1-6-34-27(31)24-19(3)29-20(4)25(28(32)35-7-2)26(24)21-12-13-22(23(18-21)33-5)36-17-11-16-30-14-9-8-10-15-30/h12-13,18,26,29H,6-11,14-17H2,1-5H3
Standard InChI Key: RTKBOKGWZATMDW-UHFFFAOYSA-N
Molfile:
RDKit 2D
36 38 0 0 0 0 0 0 0 0999 V2000
4.6366 -9.5620 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6383 -8.7437 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.3438 -8.3366 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0517 -8.7436 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0541 -9.5619 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.3445 -9.9690 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
6.7661 -9.9690 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.7655 -8.3283 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.4816 -8.7353 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.7630 -7.5100 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.3414 -7.5142 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6334 -7.1030 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6310 -6.2847 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.3447 -5.8735 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0485 -6.2846 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0468 -7.1070 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.3506 -5.0593 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
4.6509 -4.6440 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6526 -3.8298 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9488 -3.4187 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9464 -2.5962 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.2385 -2.1892 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.2360 -1.3668 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9456 -0.9597 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6536 -1.3667 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6519 -2.1891 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9221 -8.3243 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9321 -7.4977 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.2166 -8.7314 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.9228 -9.9732 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.1866 -8.3219 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.8970 -8.7257 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5090 -8.3227 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.8012 -8.7311 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.7577 -5.8786 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
7.4640 -6.2897 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 1 0
4 5 2 0
5 6 1 0
1 6 1 0
5 7 1 0
4 8 1 0
8 9 1 0
8 10 2 0
3 11 1 0
11 12 1 0
12 13 2 0
13 14 1 0
14 15 2 0
15 16 1 0
11 16 2 0
14 17 1 0
17 18 1 0
18 19 1 0
19 20 1 0
20 21 1 0
21 22 1 0
22 23 1 0
23 24 1 0
24 25 1 0
25 26 1 0
21 26 1 0
2 27 1 0
27 28 2 0
27 29 1 0
1 30 1 0
9 31 1 0
31 32 1 0
29 33 1 0
33 34 1 0
15 35 1 0
35 36 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 500.64Molecular Weight (Monoisotopic): 500.2886AlogP: 4.31#Rotatable Bonds: 11Polar Surface Area: 86.33Molecular Species: BASEHBA: 8HBD: 1#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski): 1CX Acidic pKa: ┄CX Basic pKa: 9.16CX LogP: 3.20CX LogD: 1.44Aromatic Rings: 1Heavy Atoms: 36QED Weighted: 0.36Np Likeness Score: -0.70
References 1. Malek R, Arribas RL, Palomino-Antolin A, Totoson P, Demougeot C, Kobrlova T, Soukup O, Iriepa I, Moraleda I, Diez-Iriepa D, Godyń J, Panek D, Malawska B, Głuch-Lutwin M, Mordyl B, Siwek A, Chabchoub F, Marco-Contelles J, Kiec-Kononowicz K, Egea J, de Los Ríos C, Ismaili L.. (2019) New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase Inhibition., 62 (24): [PMID:31724859 ] [10.1021/acs.jmedchem.9b00937 ]